- Home
- ACXP vs INTS Comparison
ACXP vs INTS Comparison
Compare ACXP & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- INTS
- Stock Information
- Founded
- ACXP 2017
- INTS 2012
- Country
- ACXP United States
- INTS United States
- Employees
- ACXP N/A
- INTS N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- ACXP Health Care
- INTS Health Care
- Exchange
- ACXP Nasdaq
- INTS Nasdaq
- Market Cap
- ACXP 31.4M
- INTS 33.4M
- IPO Year
- ACXP 2021
- INTS 2023
- Fundamental
- Price
- ACXP $0.78
- INTS $2.23
- Analyst Decision
- ACXP Strong Buy
- INTS Strong Buy
- Analyst Count
- ACXP 1
- INTS 3
- Target Price
- ACXP $12.00
- INTS $8.50
- AVG Volume (30 Days)
- ACXP 132.1K
- INTS 26.6K
- Earning Date
- ACXP 03-14-2025
- INTS 03-13-2025
- Dividend Yield
- ACXP N/A
- INTS N/A
- EPS Growth
- ACXP N/A
- INTS N/A
- EPS
- ACXP N/A
- INTS N/A
- Revenue
- ACXP N/A
- INTS N/A
- Revenue This Year
- ACXP N/A
- INTS N/A
- Revenue Next Year
- ACXP N/A
- INTS N/A
- P/E Ratio
- ACXP N/A
- INTS N/A
- Revenue Growth
- ACXP N/A
- INTS N/A
- 52 Week Low
- ACXP $0.67
- INTS $1.50
- 52 Week High
- ACXP $3.35
- INTS $5.94
- Technical
- Relative Strength Index (RSI)
- ACXP 49.91
- INTS 49.26
- Support Level
- ACXP $0.67
- INTS $1.84
- Resistance Level
- ACXP $0.76
- INTS $2.27
- Average True Range (ATR)
- ACXP 0.04
- INTS 0.28
- MACD
- ACXP 0.00
- INTS -0.01
- Stochastic Oscillator
- ACXP 75.28
- INTS 56.36
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.